VIDEO: Individualized therapy for migraine still needed

DENVER – More data are still needed on proper dosing of patients with eptinezumab for migraine prevention, Rami Apelian, MD, MPH, FAES, said at the American Headache Society’s annual scientific meeting.

“There were some individual characteristics [observed in the study], but they didn’t consistently carry over,” Apelian, of Huntington Headache and Neurology in Arcadia, Calif., said. “What this tells us is that we do need to continue to individualize therapy, based off of our patient’s needs.”